SNRI plus atypical antipsychotic combination

This page covers all SNRI plus atypical antipsychotic combination drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Serotonin transporter (SERT), norepinephrine transporter (NET), dopamine D2 receptor.

Targets

Serotonin transporter (SERT), norepinephrine transporter (NET), dopamine D2 receptor

Marketed (1)

• venlafaxine XR plus aripiprazole · University of Pittsburgh · Psychiatry / Mental Health
  Venlafaxine XR inhibits serotonin and norepinephrine reuptake while aripiprazole acts as a dopamine D2 receptor partial agonist, together addressing both depressive and psychotic symptoms.

Patent intelligence

• snri plus atypical antipsychotic combination patent landscape — aggregated cliff calendar, attackable patents, originator estates